Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Prolonged exposure to reduced levels of androgen accelerates prostate cancer progression in Nkx3.1; Pten mutant mice.

Banach-Petrosky W, Jessen WJ, Ouyang X, Gao H, Rao J, Quinn J, Aronow BJ, Abate-Shen C.

Cancer Res. 2007 Oct 1;67(19):9089-96.

2.

Mechanisms of prostate tumorigenesis: roles for transcription factors Nkx3.1 and Egr1.

Abdulkadir SA.

Ann N Y Acad Sci. 2005 Nov;1059:33-40. Review.

PMID:
16382041
3.

Pten inactivation and the emergence of androgen-independent prostate cancer.

Shen MM, Abate-Shen C.

Cancer Res. 2007 Jul 15;67(14):6535-8. Review.

4.

Hormone refractory prostate cancer: Lessons learned from the PTEN prostate cancer model.

Mulholland DJ, Jiao J, Wu H.

Adv Exp Med Biol. 2008;617:87-95. doi: 10.1007/978-0-387-69080-3_8. Review. No abstract available.

PMID:
18497033
5.

Molecular action of androgen in the normal and neoplastic prostate.

Kokontis JM, Liao S.

Vitam Horm. 1999;55:219-307. Review. No abstract available.

PMID:
9949683
6.

Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.

Vis AN, Schröder FH.

BJU Int. 2009 Aug;104(4):438-48. doi: 10.1111/j.1464-410X.2009.08695.x. Epub 2009 Jun 24. Review.

7.

Castration-recurrent prostate cancer is not androgen-independent.

Mohler JL.

Adv Exp Med Biol. 2008;617:223-34. doi: 10.1007/978-0-387-69080-3_21. Review.

PMID:
18497046
8.

Hormones and prostate cancer: what's next?

Hsing AW.

Epidemiol Rev. 2001;23(1):42-58. Review.

9.

Molecular mechanisms of prostate cancer.

Porkka KP, Visakorpi T.

Eur Urol. 2004 Jun;45(6):683-91. Review.

PMID:
15149739
10.

Manipulation of androgens and alterations in the androgen receptor axis in prostate cancer.

Nguyen MM, Wang Z.

Minerva Urol Nefrol. 2008 Mar;60(1):15-29. Review.

PMID:
18427432
11.

[Prostatic cancer and its androgen-dependency].

Shimazaki J, Isaka S, Akimoto S, Sumiya H, Ichikawa T, Akakura K, Furuya Y.

Gan No Rinsho. 1989 May;Spec No:268-76. Review. Japanese. No abstract available.

PMID:
2513430
12.

The significance of key regulators of apoptosis in the development and prognosis of prostate carcinoma. II. Products of suppressor genes Rb and PTEN, CDKI, Fas.

Knillová J, Kolár Z, Hlobilková A.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2003 Nov;147(1):11-7. Review.

13.

Roles of the Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis.

Shen MM, Abate-Shen C.

Dev Dyn. 2003 Dec;228(4):767-78. Review.

14.
15.

[The loss of androgen-dependency and its molecular mechanism].

Sato B, Nakamura N, Nonomura N, Matsumoto K.

Gan No Rinsho. 1989 May;Spec No:261-7. Review. Japanese. No abstract available.

PMID:
2689666
16.

Apoptosis in prostate cancer. Molecular basis to study hormone refractory mechanisms.

Colombel M, Gil Diez S, Radvanyi F, Buttyan R, Thiery JP, Chopin D.

Ann N Y Acad Sci. 1996 Apr 30;784:63-9. Review. No abstract available.

PMID:
8651618
17.

[Modern approaches to treating locally-advanced and disseminated prostate cancer].

Veliev EI.

Ter Arkh. 2002;74(10):67-70. Review. Russian. No abstract available.

PMID:
12469638
18.

Genetically engineered mouse models of prostate cancer.

Parisotto M, Metzger D.

Mol Oncol. 2013 Apr;7(2):190-205. doi: 10.1016/j.molonc.2013.02.005. Epub 2013 Feb 14. Review.

19.

Cells of origin for cancer: an updated view from prostate cancer.

Xin L.

Oncogene. 2013 Aug 8;32(32):3655-63. doi: 10.1038/onc.2012.541. Epub 2012 Nov 26. Review.

20.
Items per page

Supplemental Content

Write to the Help Desk